Wellness & Lifestyle

Convexia offers an advanced AI platform designed to revolutionize drug sourcing and evaluation. It employs an end-to-end AI stack to identify and assess drug assets, significantly reducing the time and effort typically spent on manual diligence. The platform features an Asset Discovery Agent that scans globally for overlooked drug candidates, a Scientific Evaluation Stack with over 50 custom-tuned models for in silico simulations (binding, toxicity, ADME/PK), and a Market Insight Agent to rank assets based on market factors. Additionally, an Operational Risk Agent models execution risk, and a Probability of Success Model predicts likelihood of success. Human experts are integrated at multiple stages for review and validation, ensuring accuracy and trust in the AI-driven process. Convexia aims to accelerate the development of high-potential therapeutics by providing comprehensive insights from discovery to market.

Atomwise leverages an advanced AI superplatform to revolutionize drug discovery by exploring the vast universe of chemical space. This platform is designed to identify novel, drug-like molecules that might otherwise remain undiscovered. By applying machine learning techniques, Atomwise aims to enhance the drug discovery process, particularly in the development of small-molecule drugs. The company focuses on creating programs that deliver first- and best-in-class potential, especially within immune and inflammatory diseases. Their approach is driven by a world-class team of scientists and engineers dedicated to redefining how new medications are brought to light.

Absci is a clinical-stage biopharmaceutical company leveraging generative AI to advance innovative therapeutics. Its Integrated AI Drug Creation Platform combines wet lab and AI in iterative cycles to build AI models that unlock differentiated biology and design better biologics faster. This platform enables de novo design of biologics, multi-parametric lead optimization, and AI-enabled novel target discovery using Reverse Immunology. Absci aims to accelerate biologics discovery and create life-changing medicines for patients by designing differentiated antibodies, such as ABS-201 for androgenetic alopecia, and bringing them from concept to clinical trial pipeline in 24 months.

Simulations Plus, Inc. provides comprehensive modeling and simulation software and expert consulting services to support the entire drug development lifecycle, from discovery to commercialization. Their solutions integrate AI and machine learning with advanced biosimulation techniques such as PBPK/pharmacokinetics, quantitative systems pharmacology, and pharmacometrics. Key software offerings include GastroPlus® for absorption and pharmacokinetics, MonolixSuite™ for pharmacometrics analysis, and ADMET Predictor® for AI-driven drug design and ADMET modeling. The company's tools are designed to enhance decision-making in drug development, offering mechanistic models and AI-enabled workflows for increased confidence and efficiency.

Curebase is an AI-native eClinical platform designed to unify sponsors and sites on a single system, accelerating clinical trials from study startup to database lock. It provides a comprehensive suite of tools including ePRO/eCOA for patient-reported outcomes, eConsent for electronic informed consent, Electronic Data Capture (EDC), and robust patient recruitment capabilities. The platform also features dedicated site software (Sitebase) to streamline patient management and automate workflows for research sites. Curebase aims to improve data quality and boost participant engagement, adapting to the needs of biotech, MedTech, pharma, and CROs, making it suitable for lean teams and global programs alike.

PROTAC Scientific-Drug Discovery Pro provides comprehensive computational services to accelerate drug lead discovery. The platform utilizes cutting-edge machine learning and informatics tools, alongside in-house multidisciplinary expertise, to streamline the drug discovery process from strategy development through publication. Services include fragment-based lead discovery, molecular docking, protein homology modeling, pharmacophore modeling, and the creation of customized machine learning models for bioactivity prediction. They also offer training programs and workshops, and support for publishing in top-tier journals and patenting. The company aims to reduce costs and save time for researchers, with financial support options for students and referral programs.

Meddenovo Drug Design is a Lyon-based biotech company specializing in AI-powered, nature-inspired cyclic peptide design. Their platform, Mexa, combines large-scale AI-driven generation with physics-based evaluation and refinement to explore millions of candidate peptides per target. This technology allows for de novo drug design even without prior experimental data, accelerating hit identification in drug discovery. Meddenovo focuses on reducing early discovery risk and unlocking peptide-based modalities for difficult targets, particularly in oncology, radiopharmaceuticals, and metabolic diseases. Their approach leverages the unique properties of cyclic peptides, which bridge small molecules and biologics, offering structural rigidity for selective target binding and versatility for complex biological interfaces.

Temedica is a technology, AI, and data-enabled solution and service provider specifically for the pharmaceutical industry. It empowers pharma companies to achieve exceptional brand performance through a holistic strategy and tactical execution. By combining real-world insights, configurable AI-powered solutions, omnichannel patient & HCP engagement, and deep medical expertise, Temedica helps transform commercial and medical challenges into tangible success. The platform offers solutions like the Permea Insight Hub for tailored real-world insights and the Omnichannel Engagement Suite for automated, compliant engagement across patients and HCPs. Temedica supports various use cases including market insights, competitive benchmarking, launch excellence, brand strategy, stakeholder engagement, patient journey analysis, and real-world evidence generation.

Aurora Analytica is an AI-powered clinical intelligence platform designed to optimize clinical trial design, planning, and execution. It transforms lengthy 7-10 day proposal cycles into efficient, AI-assisted decision workflows, enabling Contract Research Organizations (CROs) and pharmaceutical companies to create stronger bids and validate strategies. The platform features the Aurora Suite, which includes core decision engines like Trial Core for global trial records, Geo Matrix for country and site strategy, Plume for dynamic intelligence, and Simulator-L for scenario modeling. It aims to reduce feasibility prep time from days to hours, improve strategy NPS, and provide comprehensive trial intelligence.

Anthropic Healthcare provides a marketplace of Claude Code Skills specifically designed for healthcare workflows. This includes tools for generating FDA/NIH-compliant clinical trial protocols, performing initial checks and summarizing arguments for medical necessity in prior authorization reviews, and accelerating healthcare system integration with specialized knowledge of HL7 FHIR R4. It supports healthcare data exchange, including resource structures, coding systems like LOINC, SNOMED CT, and RxNorm, and validation patterns. The platform also offers access to remote MCP servers for CMS Coverage, NPI Registry, and PubMed, enabling comprehensive data access for healthcare professionals.

Minicule is an AI-powered platform designed to transform complex research data into clear, actionable knowledge graphs, primarily for life science researchers. It offers features like basic and advanced knowledge graph visualization, publication search, and timeline views. Users can start with a free tier offering 1 million tokens per month and 1 GB storage, or upgrade to Pro or Team plans for private modes, increased storage, and collaboration features. An Enterprise option provides custom solutions, BYO LLM keys, Docker deployment, and dedicated support, making it suitable for individual researchers up to large organizations.

Xbiome, also known as 未知君, is a leading AI microbiome research and industrial transformation platform in China. The company focuses on developing micro-ecological treatments, including formulated bacteria and genetically engineered microorganisms, to alleviate or treat intestinal and other systemic diseases. By integrating artificial intelligence with gut microbiome technology, Xbiome enhances data analysis, accumulation, and output, significantly improving the efficiency and success rate of drug development. Additionally, Xbiome researches and develops fecal microbiota transplantation solutions, probiotic products, and industry solutions, moving micro-ecology from scientific exploration to industrial application.

XCMR leads in biosecurity innovation by integrating UVC technology into a range of devices, including wearables, portable units, and stationary systems, specifically designed to prevent the transmission of infectious diseases. The company's advanced IoT cloud platform leverages AI-driven predictive analytics to enhance visibility, response capabilities, and preparedness for scaled infection transmission resiliency. This approach is grounded in scientific research and aims to improve health security for all. XCMR Inc. focuses on advanced next-generation biological threat protection, offering solutions for biodefense.

NextTrial AI provides a unified intelligence platform designed for the life sciences industry, offering AI-driven solutions to accelerate clinical research, enhance drug safety, and ensure regulatory compliance. The platform features Study 360 for streamlining study design and patient recruitment, Total Safety Intelligence for end-to-end safety management and proactive signal detection, and Regulatory Navigator for tracking global regulations and automating impact assessments. It operates on a Unified Data Hub, enabling collaborative analytics and workflows, and leverages an AI Foundation with GenAI, agentic AI, and predictive models. The platform ensures real-time oversight with a 360° view of data streams, insights, and actions, all within a secure, compliant, and validated cloud environment.

Intrepid Labs is dedicated to accelerating therapeutics development by leveraging a unique closed-loop technology that combines active machine learning, advanced robotics, and extensive pharmaceutical expertise. The company focuses on revolutionizing the design of next-generation drug products, aiming to improve their properties and performance for better patient outcomes. Their approach involves a multidisciplinary team of experts in quantum information, machine learning, chemistry, drug development, and applied mathematics. Intrepid Labs is a Johnson & Johnson Innovation - JLABS resident company and a member of the Vector Institute’s Fast-Lane Program, highlighting its commitment to innovation in the pharmaceutical sector.

Menten AI leverages generative AI to revolutionize peptide drug design, focusing on unlocking the potential of peptides and macrocycles for life-changing medicines. Their flagship platform, MAUD 1.0, is designed to create peptide macrocycles de novo for challenging drug targets, including Protein-Protein Interfaces. Validated across preclinical discovery, MAUD 1.0 has demonstrated nM-level potency, oral bioavailability, and cell-permeability with a high hit rate. Unlike traditional screening, the platform integrates generative AI with physics-based models and quantum simulations to accelerate discovery and expand the accessible chemical space for drug-like peptides.

Leman Biotech is a clinical-stage company specializing in the development of innovative cancer immunotherapies. Founded by a team from EPFL and XtalPi, the company leverages a unique combination of immune metabolic reprogramming and advanced artificial intelligence. Their core technologies include a metabolic reprogramming macromolecule platform (Meta 10) to reactivate exhausted T-cells, a metabolic-enhanced cell therapy platform, and an AI super-factor platform for efficient computational design of biomacromolecules. Leman Biotech focuses on researching, producing, and commercializing new oncology treatments, with recent successes including FDA IND approval for their META 10-19 injection and positive clinical trial results for their metabolic-enhanced CAR-T therapy.

DeepRoot Minds is a born-AI company specializing in healthcare intelligence, mental wellness companions, and enterprise ontology platforms. Rooted in truth, their AI systems leverage ontology-driven knowledge graphs to prevent hallucinations, ensuring verifiable and traceable answers. They offer HealthTech solutions like mobile diagnostics for dermatology, ophthalmology, and dental AI, providing clinical insights from smartphone photos. For mental health, they develop advanced AI platforms embodied in social robots for longitudinal care, starting with pediatric applications. Additionally, DeepRoot Minds provides enterprise ontology platforms and knowledge graphs to eliminate AI hallucinations across various products and agents, with a focus on provenance-aware and graph-grounded retrieval.

The Collaborative AI Research Labs Foundation (CAiRL) is a non-profit organization focused on fostering collaboration and ethical innovation within the AI research community. CAiRL aims to advance AI for social good, with a particular emphasis on applications in bio-pharma, healthcare, and Agri-Tech sectors. Through its initiatives, the foundation ensures that AI development benefits society responsibly and sustainably, promoting research, education, and ethical guidelines. CAiRL serves as a platform for various AI research labs to unite their efforts, share knowledge, and collectively address complex challenges, ultimately driving positive societal impact through artificial intelligence.

Opyl is an AI-driven platform specifically designed for biostatistical validation and optimizing clinical trial designs. It leverages artificial intelligence to simulate trials, analyze complex datasets from clinical studies, and provide data-backed recommendations. This allows for more efficient and effective strategic planning and decision-making within the pharmaceutical and biotech sectors. Opyl supports companies of all sizes in streamlining trial outcomes, from early-stage drug candidate selection to real-time recruitment analytics, ultimately aiming to accelerate the development of new therapies.

Biographica is an advanced AI platform dedicated to revolutionizing crop improvement through gene-editing. The tool leverages cutting-edge machine learning and high-throughput sequencing to identify and prioritize novel, high-quality genetic targets for any trait in any crop. It analyzes each target within its full biological context, moving beyond 'low-hanging fruit' to identify targets with maximal efficacy and minimal undesired pleiotropic effects. Biographica aims to streamline the gene-editing pipeline, increasing success rates, saving time, and cutting costs for trait developers. The platform integrates deep multi-modal in silico screening, context-aware edit design, in planta validation, and iterative re-integration of validation data to continuously improve future screens.

ViridisChem offers an AI-powered chemistry platform designed for R&D and EHS teams. The platform enables users to find safer reagents, generate OSHA/GHS compliant Safety Data Sheets (SDS) for chemicals and mixtures, and receive ADMET characteristics of novel molecules. It also allows for the assessment of reaction performance, helping to minimize late-stage product development changes and optimize processes. Key features include a Chemical Analyzer for comprehensive chemical profiles and selecting less toxic alternatives, an SDS Generator for automatic compliance, and a Reaction Analyzer for predictive scores on performance, toxicity, and scalability. The tool aims to empower toxicity-aware smart decisions and enhance lab safety.

Aiosyn specializes in AI-powered pathology software, focusing on cancer and chronic kidney disease biomarkers. Their solutions improve digital pathology workflows and facilitate informed decision-making in drug development and clinical diagnostics. Key offerings include AiosynQC for automated quality control of digital histology slides, Aiosyn Mitosis Breast for identifying mitotic figures in breast H&E sections, and the NephroPath platform for precise quantification of kidney lesion scores. Aiosyn also provides services like external digital slide quality assessments and kidney image analysis, supporting pathology labs and biopharma with consistent and efficient analyses without requiring complex integration.

DigiBiomics leverages AI and precision diagnostics to bridge the gap between symptoms and answers in healthcare. The platform integrates science and artificial intelligence to facilitate earlier disease detection, smarter care delivery, and improved patient outcomes globally. It offers services such as tailored AI models for analyzing medical data and generating evidence-based diagnoses, Data as a Service (DaaS) for secure clinical data provision, and end-to-end automation for digital transformation of healthcare systems. DigiBiomics also fosters collaboration and training with academic institutions and healthcare organizations to promote AI adoption and digital literacy, ultimately empowering care teams to act faster and save lives.